Rational
India
China
Japan
Pakistan
Bangladesh
South Korea
Israel
Palestine
Iran
Saudi Arabia
United Arab Emirates
Türkiye
Egypt
United Kingdom
France
Germany
Ukraine
Russia
United States
Canada
Brazil
Nigeria
South Africa
Australia Verified · 13 outletsBusiness
Ozempic, Wegovy and other GLP-1 drugs to carry vision loss warning after FDA finds rare eye risk
Headline via Hindustan Times · first report 9 Nov, 21:26 IST, latest 11 Nov, 11:54 IST
What we know
13 independent news organisations have reported this story. The first report we saw came from STAT at 9 Nov, 21:26 IST; the latest is from The Hindu BusinessLine at 11 Nov, 11:54 IST. Rational Times has not independently confirmed the details: read each report through the links below.
StatusVerified
Reported by13 news organisations
First report9 Nov, 21:26 IST
Latest report11 Nov, 11:54 IST
DeskBusiness
What the reports sayEach newsroom’s own summary of its report, from its feed
The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
The Food and Drug Administration said the risk will be added to the labeling of all GLP-1 drugs, the blockbuster medications used to treat obesity, diabetes and several other medical conditions.
The eye condition, known as non-arteritic anterior ischemic optic neuropathy, can cause significant vision loss and has been reported with all GLP-1 drugs,
US regulators say the rare eye condition NAION can cause permanent vision loss. All GLP-1 drugs, including Ozempic and Wegovy, will now carry the warning.
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Quoted from the newsrooms’ own feeds, with their names and links. Rational Times has not independently confirmed the details.
The reports18 reports
- STAT STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
- MarketWatch Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
- NDTV Ozempic, Wegovy, Mounjaro Face New FDA Warning Over Potential Risk Of Serious Vision Loss
- Times Now Ozempic, Wegovy And Mounjaro May Carry Rare Blindness Risk, FDA Warns
- NDTV New US FDA Warning Links Rare Vision Loss To Widely Used GLP-1 Drugs
- The Hindu FDA adds rare vision-loss warning to popular obesity, diabetes drugs
- Hindustan Times Ozempic, Wegovy and other GLP-1 drugs to carry vision loss warning after FDA finds rare eye risk
- CNBC FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
- Mint FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
- The Independent Weight loss drugs linked to new rare side effect as new warning labels required
- STAT STAT+: GLP-1s are given an FDA warning for rare eye condition risk
- Ars Technica FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
- BBC News Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
- The Economic Times GLP-1 drugs for weight loss linked to vision loss
- The Guardian FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
- Medical Xpress Rare eye condition prompts new FDA warning on popular GLP-1 drugs
- Times Now Top US Expert Explains Why Protein Is Non-Negotiable For People Taking GLP-1 Weight-Loss Drugs
- The Hindu BusinessLine FDA flags possible risk of rare eye condition with GLP-1 drugs, orders new safety warning
Headlines belong to the news organisations named; each links to their own report. We group reports automatically by their key words, so now and then two different stories can be grouped together, or one story split in two. Tell us about a mistake
